Viridian Therapeutics, Inc. | Mid-cap | Energy

Financial Overview

Latest Annual: 2024

Income Metrics

Revenue 1.2B
Gross Profit 340.2M 28.08%
Operating Income 202.4M 16.71%
Net Income 50.8M 4.19%
EPS (Diluted) €6.93

Balance Sheet Metrics

Total Assets 2.8B
Total Liabilities 1.7B
Shareholders Equity 1.1B
Debt to Equity 1.53

Cash Flow Metrics

Operating Cash Flow 48.4M
Free Cash Flow 171.7M

Revenue & Profitability Trend

Viridian Income Statement From 2020 to 2024

Metric20242023202220212020
Revenue1.2B1.1B927.4M1.1B886.7M
Cost of Goods Sold871.2M817.4M654.9M853.2M726.5M
Gross Profit340.2M258.4M272.5M209.8M160.2M
Operating Expenses137.8M138.0M116.8M109.8M333.5M
Operating Income202.4M120.4M155.7M100.0M41.2M
Pre-tax Income50.1M19.9M83.5M-186.1M-346.8M
Income Tax13.4M14.0M17.2M-4.4M29.3M
Net Income50.8M16.2M43.3M-180.0M-436.8M
EPS (Diluted)€6.93€2.00€6.00-€25.00-€62.00

Income Statement Trend

Viridian Balance Sheet From 2020 to 2024

Metric20242023202220212020
Assets
Current Assets926.2M973.7M1.0B1.0B1.2B
Non-Current Assets1.9B1.9B1.9B1.9B2.1B
Total Assets2.8B2.9B2.9B2.9B3.4B
Liabilities
Current Liabilities507.0M550.3M554.3M585.2M716.9M
Non-Current Liabilities1.2B1.3B1.3B1.3B1.5B
Total Liabilities1.7B1.9B1.8B1.9B2.2B
Equity
Total Shareholders Equity1.1B1.1B1.1B1.0B1.2B

Balance Sheet Composition

Viridian Cash Flow Statement From 2020 to 2024

Metric20242023202220212020
Operating Activities
Net Income36.1M3.9M47.8M-181.6M-407.9M
Operating Cash Flow48.4M167.3M80.0M-82.0M-264.1M
Investing Activities
Capital Expenditures6.8M-60.5M40.5M-54.9M-63.6M
Investing Cash Flow-1.5M-61.4M6.4M29.5M-37.2M
Financing Activities
Dividends Paid-----
Financing Cash Flow-59.3M22.2M12.6M-67.2M-5.1M
Free Cash Flow171.7M176.3M85.7M109.8M-38.8M

Cash Flow Trend

Viridian Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) 50.43
Forward P/E 5.52
Price to Book 0.40
Price to Sales 0.34
PEG Ratio 5.52

Profitability Ratios

Profit Margin 2.05%
Operating Margin 21.93%
Return on Equity 0.93%
Return on Assets 4.95%

Financial Health

Current Ratio 1.54
Debt to Equity 103.04
Beta 1.37

Per Share Data

EPS (TTM) €1.15
Book Value per Share €146.51
Revenue per Share €170.52

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
viri415.4M50.430.400.93%2.05%103.04
Medincell S.A 565.5M-18.81-61.33%-66.50%-1.44
Valneva SE 409.5M70.642.11-44.11%-43.21%120.48
BNP Paribas Easy 456.7M15.91--96.39%-27.22%2.22
Abivax SA 331.7M-1.96-52.78-196.12%0.00%-16.16
Inventiva S.A 379.0M-0.88-0.99172.73%0.00%-1.70

Financial data is updated regularly. All figures are in the company's reporting currency.